These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37004220)

  • 1. Comparative Efficacy of Treatment Options for the Prevention of Post-TIPS Hepatic Encephalopathy: A Systematic Review and Network Meta-analysis.
    Ahmed Z; Hassan M; Arif SF; Aziz M; Iqbal U; Nawaz A; Farooq U; Smith WL; Badal J; Renno A; Javaid T; Nawras A; Saab S
    J Gastrointestin Liver Dis; 2023 Apr; 32(1):70-76. PubMed ID: 37004220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial).
    de Wit K; Schaapman JJ; Nevens F; Verbeek J; Coenen S; Cuperus FJC; Kramer M; Tjwa ETTL; Mostafavi N; Dijkgraaf MGW; van Delden OM; Beuers UHW; Coenraad MJ; Takkenberg RB
    BMJ Open Gastroenterol; 2020 Dec; 7(1):. PubMed ID: 33372103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary prevention of hepatic encephalopathy post-TIPS: A systematic review and meta-analysis.
    Liang A; Brar S; Almaghrabi M; Khan MQ; Qumosani K; Teriaky A
    Medicine (Baltimore); 2023 Sep; 102(38):e35266. PubMed ID: 37746955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
    Bureau C; Thabut D; Jezequel C; Archambeaud I; D'Alteroche L; Dharancy S; Borentain P; Oberti F; Plessier A; De Ledinghen V; Ganne-Carrié N; Carbonell N; Rousseau V; Sommet A; Péron JM; Vinel JP
    Ann Intern Med; 2021 May; 174(5):633-640. PubMed ID: 33524293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.
    Dhiman RK; Thumburu KK; Verma N; Chopra M; Rathi S; Dutta U; Singal AK; Taneja S; Duseja A; Singh M
    Clin Gastroenterol Hepatol; 2020 Apr; 18(4):800-812.e25. PubMed ID: 31476436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.
    Fu J; Gao Y; Shi L
    PLoS One; 2022; 17(4):e0267647. PubMed ID: 35471992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin.
    Seifert LL; Schindler P; Schoster M; Weller JF; Wilms C; Schmidt HH; Maschmeier M; Masthoff M; Köhler M; Heinzow H; Wildgruber M
    J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Variable Treatment Options in the Prevention of Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.
    Hammd M; Elghezewi A; Abdulhadi A; Alabid A; Alabid A; Badi Y; Kamal I; Hesham Gamal M; Mohamed Fisal K; Mujtaba M; Sherif A; Frandah W
    Cureus; 2024 Jan; 16(1):e53341. PubMed ID: 38435950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
    Sanyal AJ; Kowdley KV; Reau NS; Pyrsopoulos NT; Allen C; Heimanson Z; Bajaj JS
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38727685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
    Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy.
    Wang Z; Chu P; Wang W
    Drug Des Devel Ther; 2019; 13():1-11. PubMed ID: 30587923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.
    Jesudian AB; Ahmad M; Bozkaya D; Migliaccio-Walle K
    J Manag Care Spec Pharm; 2020 Jun; 26(6):750-757. PubMed ID: 32463782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
    Higuera-de-la-Tijera F; Servín-Caamaño AI; Salas-Gordillo F; Pérez-Hernández JL; Abdo-Francis JM; Camacho-Aguilera J; Alla SN; Jiménez-Ponce F
    Can J Gastroenterol Hepatol; 2018; 2018():3015891. PubMed ID: 30079329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy.
    Moon AM; Kim HP; Jiang Y; Lupu G; Bissram JS; Barritt AS; Tapper EB
    Am J Gastroenterol; 2023 Feb; 118(2):284-293. PubMed ID: 36730910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
    Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
    J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.